Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595607 | 1.00 | CCR5 (0.56) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL3591589 | 0.87 | CCR5 (0.43) | CCR5CYP3A4KCNH2 | |
| SCHEMBL3604754 | 0.81 | CCR5 (0.47) | CCR5KCNH2 | |
| SCHEMBL3593750 | 0.76 | CCR5 (0.53) | CCR5KCNH2 | |
| SCHEMBL3604590 | 0.75 | CCR5 (0.51) | CCR5CYP3A4KCNH2 | |
| SCHEMBL3607166 | 0.73 | CCR5 (0.43) | CCR5CYP3A4CYP2C9KCNH2 | |
| SCHEMBL3603950 | 0.73 | CCR5 (0.43) | CCR5CYP3A4CYP2C9KCNH2 | |
| SCHEMBL3603948 | 0.73 | CCR5 (0.43) | CCR5CYP3A4CYP2C9KCNH2 | |
| SCHEMBL3595208 | 0.72 | CCR5 (0.61) | CCR5CYP3A4KCNH2 | |
| SCHEMBL4581898 | 0.72 | CCR5 (0.56) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| EP-1742934-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | CCR5 1/4885CYP3A4 1516/4885ADRA2A 54/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | CCR5 1/4885CYP3A4 294/4885ADRA2A 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.